Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : plans 670 job cuts in France by end 2020

share with twitter share with LinkedIn share with facebook
share via e-mail
12/05/2018 | 12:09pm EDT
The logo of Sanofi is pictured during the Viva Tech start-up and technology summit in Paris

PARIS (Reuters) - French drugmaker Sanofi told unions on Wednesday it was planning to cut 670 jobs in France, a union representative told Reuters.

The plan, which is to be set on a voluntary basis, would affect human resources, IT, and finances among others, Thierry Bodin, with the CGT union said. In addition, 80 IT jobs are to be outsourced, he said.

"This is a terrible loss of expertise. It will have consequences in terms of efficiency," Bodin said.

Sanofi had said in September it would continue to implement cost savings after having reached a 1.5 billion euros (1.34 billion pounds) cost reduction target a year ahead of expectations.

"We are blindsided as Sanofi makes significant amounts of profits. And at a time of strong social tensions in France, the government is looking the other way," Bodin said in reference to the so-called "yellow vest" protests which led to the worst riots seen in central Paris in five decades last Saturday.

A Sanofi spokesman confirmed the company's intention to shed 670 jobs out of a 25,000 workforce in France and said the plan was to be completed by the end of 2020.

At the same time, Sanofi will invest 700 million euros in France to upgrade its production sites, notably in the areas of vaccines manufacturing and other biologic medicines.

(Reporting by Matthias Blamont; Editing by Leigh Thomas and Mathieu Rosemain)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
04/15SANOFI AVENTIS : Board of Directors meeting of Sanofi-Aventis Pakistan Limited
04/11SANOFI : Health Canada issues Notice of Compliance with Conditions (NOC/c) for L..
04/10SANOFI : Disclosure of trading in own shares
04/10Sanofi to cut U.S. insulin costs for some patients to $99 per month
04/10SANOFI : provides unprecedented access to its insulins for one set monthly price
04/10ALNYLAM PHARMACEUTICALS : inks broad R&D deal with Regeneron
04/09SANOFI : boosts pharma logistics capacity in Dubai with Kuehne + Nagel
04/09SANOFI : and Alnylam conclude research phase of RNAi alliance
04/09SANOFI : and Alnylam conclude research and option phase of 2014 rare disease all..
04/08Sanofi and Alnylam conclude research and option phase of 2014 rare disease al..
More news
Financials (€)
Sales 2019 36 142 M
EBIT 2019 9 204 M
Net income 2019 5 015 M
Debt 2019 14 167 M
Yield 2019 4,37%
P/E ratio 2019 16,62
P/E ratio 2020 14,65
EV / Sales 2019 2,91x
EV / Sales 2020 2,70x
Capitalization 90 952 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 83,6 €
Spread / Average Target 15%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-3.69%102 274
JOHNSON & JOHNSON6.56%366 184
ROCHE HOLDING LTD.8.22%224 627
PFIZER-9.78%218 630
NOVARTIS3.69%194 472
MERCK AND COMPANY-4.21%189 055